Literature DB >> 16019947

In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis.

J H Ansede1, R D Voyksner, M A Ismail, D W Boykin, R R Tidwell, J E Hall.   

Abstract

A new aza-analogue of furamidine, 6-[5-(4-amidinophenyl)-furan-2-yl]nicotinamidine (DB820), has potent in vitro antitrypanosomal activity; however, it suffers from poor oral activity because of its positively charged amidine groups. The dimethoxyamidine prodrug of DB820, N-methoxy-6-{5-[4-(N-methoxyamidino)phenyl]-furan-2-yl}-nicotinamidine (DB844), has potent oral activity in mouse models of both early-stage and CNS African trypanosomiasis. Metabolism of DB844 in human liver microsomes (HLM) was investigated using liquid chromatography-mass spectrometry (LC-MS/MS). The metabolism of DB844 in HLM was NADPH-dependent and resulted in the production of eight metabolites over a 90?min incubation. O-Demethylation and N-dehydroxylation reactions resulted in the metabolic conversion of DB844 to its active DB820 metabolite. Chromatographic conditions used for LC-MS analysis allowed for the separation and identification of all metabolites including positional isomers. Demethylation of either the phenyl or pyridine side of DB844 (DB844 m/z 366.2) resulted in the production of two metabolites (M1A, M1B), each with a molecular ion of m/z of 352.3 and MS(2) fragments of 288.1, 305.2, 321.2 and 335.2. However, the intensities of the MS(2) fragments were different among the two isomeric metabolites, and comparison to an authentic standard allowed for the structural determination of each metabolite. The isomeric metabolites M2A and M2B, resulting from amidoxime reductions of M1A and M1B, were also chromatographically separated and had distinguishable MS(2) profiles that allowed for their structural assignments when compared to an authentic standard. The di-amidoxime product resulting from O-demethylation of either side of DB844 was also identified as an abundant metabolite during microsomal incubations. The active antitrypanosomal metabolite, DB820, was the last metabolite to be formed and thus provides evidence that DB844 may effectively be metabolized to its active metabolite in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019947     DOI: 10.1080/00498250500087671

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  16 in total

Review 1.  Antiparasitic compounds that target DNA.

Authors:  W David Wilson; Farial A Tanious; Amanda Mathis; Denise Tevis; James Edwin Hall; David W Boykin
Journal:  Biochimie       Date:  2008-03-04       Impact factor: 4.079

2.  Synthesis and antiprotozoal activity of dicationic 2,6-diphenylpyrazines and aza-analogues.

Authors:  Laixing Hu; Alpa Patel; Lavanya Bondada; Sihyung Yang; Michael Zhuo Wang; Manoj Munde; W David Wilson; Tanja Wenzler; Reto Brun; David W Boykin
Journal:  Bioorg Med Chem       Date:  2013-08-13       Impact factor: 3.641

3.  Metabolism studies of a small-molecule tumor necrosis factor-alpha (TNF-α) inhibitor, UTL-5b (GBL-5b).

Authors:  Jiajiu Shaw; Brian Shay; Jack Jiang; Frederick Valeriote; Ben Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-11-05       Impact factor: 2.441

Review 4.  The mammalian molybdenum enzymes of mARC.

Authors:  Gudrun Ott; Antje Havemeyer; Bernd Clement
Journal:  J Biol Inorg Chem       Date:  2014-11-26       Impact factor: 3.358

5.  Synthesis and antiprotozoal activity of 2,5-bis[amidinoaryl]thiazoles.

Authors:  Danuta Branowska; Abdelbasset A Farahat; Arvind Kumar; Tanja Wenzler; Reto Brun; Yang Liu; W David Wilson; David W Boykin
Journal:  Bioorg Med Chem       Date:  2010-03-27       Impact factor: 3.641

Review 6.  State of the art in African trypanosome drug discovery.

Authors:  Robert T Jacobs; Bakela Nare; Margaret A Phillips
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

7.  New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.

Authors:  Tanja Wenzler; David W Boykin; Mohamed A Ismail; James Edwin Hall; Richard R Tidwell; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

8.  Synthesis and activity of azaterphenyl diamidines against Trypanosoma brucei rhodesiense and Plasmodium falciparum.

Authors:  Laixing Hu; Reem K Arafa; Mohamed A Ismail; Alpa Patel; Manoj Munde; W David Wilson; Tanja Wenzler; Reto Brun; David W Boykin
Journal:  Bioorg Med Chem       Date:  2009-08-07       Impact factor: 3.641

Review 9.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

Review 10.  Novel amidines and analogues as promising agents against intracellular parasites: a systematic review.

Authors:  M N C Soeiro; K Werbovetz; D W Boykin; W D Wilson; M Z Wang; A Hemphill
Journal:  Parasitology       Date:  2013-04-08       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.